The menstrual cycle is the regular natural change that occurs in the female reproductive system (specifically the uterus and ovaries) that makes pregnancy possible. The cycle is required for the production of oocytes, and for the preparation of the uterus for pregnancy. Up to 80% of women report having some symptoms during the one to two weeks prior to menstruation. Common symptoms include acne, tender breasts, bloating, feeling tired, irritability and mood changes. These symptoms interfere with normal life and therefore qualify as premenstrual syndrome in 20 to 30% of women. In 3 to 8%, they are severe.
The first period usually begins between twelve and fifteen years of age, a point in time known as menarche. They may occasionally start as early as eight, and this onset may still be normal. The average age of the first period is generally later in the developing world and earlier in developed world. The typical length of time between the first day of one period and the first day of the next is 21 to 45 days in young women and 21 to 35 days in adults (an average of 28 days). Menstruation stops occurring after menopause which usually occurs between 45 and 55 years of age. Bleeding usually lasts around 2 to 7 days.
The menstrual cycle is governed by hormonal changes. These changes can be altered by using hormonal birth control to prevent pregnancy. Each cycle can be divided into three phases based on events in the ovary (ovarian cycle) or in the uterus (uterine cycle). The ovarian cycle consists of the follicular phase, ovulation, and luteal phase whereas the uterine cycle is divided into menstruation, proliferative phase, and secretory phase.
Stimulated by gradually increasing amounts of estrogen in the follicular phase, discharges of blood (menses) flow stop, and the lining of the uterus thickens. Follicles in the ovary begin developing under the influence of a complex interplay of hormones, and after several days one or occasionally two become dominant (non-dominant follicles shrink and die). Approximately mid-cycle, 2436 hours after the luteinizing hormone (LH) surges, the dominant follicle releases an ovocyte, in an event called ovulation. After ovulation, the ovocyte only lives for 24 hours or less without fertilization while the remains of the dominant follicle in the ovary become a corpus luteum; this body has a primary function of producing large amounts of progesterone. Under the influence of progesterone, the uterine lining changes to prepare for potential implantation of an embryo to establish a pregnancy. If implantation does not occur within approximately two weeks, the corpus luteum will involute, causing a sharp drop in levels of both progesterone and estrogen. The hormone drop causes the uterus to shed its lining in a process termed menstruation. Menstruation also occurs in closely related primates (apes and monkeys).
The average age of menarche is 1215. They may occasionally start as early as eight, and this onset may still be normal. This first period often occurs later in the developing world than the developed world.
The average age of menarche is approximately 12.5 years in the United States, 12.7 in Canada, 12.9 in the UK and 13.1 years in Iceland. Factors such as genetics, diet and overall health can affect timing.
The cessation of menstrual cycles at the end of a woman's reproductive period is termed menopause. The average age of menopause in women is 52 years, with anywhere between 45 and 55 being common. Menopause before age 45 is considered premature in industrialised countries. Like the age of menarche, the age of menopause is largely a result of cultural and biological factors; however, illnesses, certain surgeries, or medical treatments may cause menopause to occur earlier than it might have otherwise.
The length of a woman's menstrual cycle typically varies somewhat, with some shorter cycles and some longer cycles. A woman who experiences variations of less than eight days between her longest cycles and shortest cycles is considered to have regular menstrual cycles. It is unusual for a woman to experience cycle length variations of more than four days. Length variation between eight and 20 days is considered as moderately irregular cycles. Variation of 21 days or more between a woman's shortest and longest cycle lengths is considered very irregular. 
The average menstrual cycle lasts 28 days. The variability of menstrual cycle lengths is highest for women under 25 years of age and is lowest, that is, most regular, for ages 25 to 39. Subsequently, the variability increases slightly for women aged 40 to 44.
The luteal phase of the menstrual cycle is about the same length in most individuals (mean 14.13 days, standard deviation 1.41 days) whereas the follicular phase tends to show much more variability (log-normally distributed with 95% of individuals having follicular phases between 10.3 and 16.3 days). The follicular phase also seems to get significantly shorter with age (geometric mean 14.2 days in women aged 1824 vs. 10.4 days in women aged 4044).
Some women with neurological conditions experience increased activity of their conditions at about the same time during each menstrual cycle. For example, drops in estrogen levels have been known to trigger migraines, especially when the woman who suffers migraines is also taking the birth control pill. Many women with epilepsy have more seizures in a pattern linked to the menstrual cycle; this is called "catamenial epilepsy". Different patterns seem to exist (such as seizures coinciding with the time of menstruation, or coinciding with the time of ovulation), and the frequency with which they occur has not been firmly established. Using one particular definition, one group of scientists found that around one-third of women with intractable partial epilepsy has catamenial epilepsy. An effect of hormones has been proposed, in which progesterone declines and estrogen increases would trigger seizures. Recently, studies have shown that high doses of estrogen can cause or worsen seizures, whereas high doses of progesterone can act like an antiepileptic drug. Studies by medical journals have found that women experiencing menses are 1.68 times more likely to attempt suicide.
Mice have been used as an experimental system to investigate possible mechanisms by which levels of sex steroid hormones might regulate nervous system function. During the part of the mouse estrous cycle when progesterone is highest, the level of nerve-cell GABA receptor subtype delta was high. Since these GABA receptors are inhibitory, nerve cells with more delta receptors are less likely to fire than cells with lower numbers of delta receptors. During the part of the mouse estrous cycle when estrogen levels are higher than progesterone levels, the number of delta receptors decrease, increasing nerve cell activity, in turn increasing anxiety and seizure susceptibility.
Estrogen levels may affect thyroid behavior. For example, during the luteal phase (when estrogen levels are lower), the velocity of blood flow in the thyroid is lower than during the follicular phase (when estrogen levels are higher).
Among women living closely together, it was once thought that the onsets of menstruation tend to synchronize. This effect was first described in 1971, and possibly explained by the action of pheromones in 1998. Subsequent research has called this hypothesis into question.
Research indicates that women have a significantly higher likelihood of anterior cruciate ligament injuries in the pre-ovulatory stage, than post-ovulatory stage.
The most fertile period (the time with the highest likelihood of pregnancy resulting from sexual intercourse) covers the time from some 5 days before until 1 to 2 days after ovulation. In a 28day cycle with a 14day luteal phase, this corresponds to the second and the beginning of the third week. A variety of methods have been developed to help individual women estimate the relatively fertile and the relatively infertile days in the cycle; these systems are called fertility awareness.
There are many fertility testing methods, including urine test kits that detect the LH surge that occurs 24 to 36 hours before ovulation; these are known as ovulation predictor kits (OPKs). Computerized devices that interpret basal body temperatures, urinary test results, or changes in saliva are called fertility monitors. Fertility awareness methods that rely on cycle length records alone are called calendar-based methods. Methods that require observation of one or more of the three primary fertility signs (basal body temperature, cervical mucus, and cervical position) are known as symptoms-based methods.
A woman's fertility is also affected by her age. As a woman's total egg supply is formed in fetal life, to be ovulated decades later, it has been suggested that this long lifetime may make the chromatin of eggs more vulnerable to division problems, breakage, and mutation than the chromatin of sperm, which are produced continuously during a man's reproductive life. However, despite this hypothesis, a similar paternal age effect has also been observed.
As measured on women undergoing in vitro fertilization, a longer menstrual cycle length is associated with higher pregnancy and delivery rates, even after age adjustment.Delivery rates after IVF have been estimated to be almost doubled for women with a menstrual cycle length of more than 34 days compared with women with a menstrual cycle length shorter than 26 days. A longer menstrual cycle length is also significantly associated with better ovarian response to gonadotropin stimulation and embryo quality.
The different phases of the menstrual cycle correlate with women's moods. In some cases, hormones released during the menstrual cycle can cause behavioral changes in females; mild to severe mood changes can occur. The menstrual cycle phase and ovarian hormones may contribute to increased empathy in women. The natural shift of hormone levels during the different phases of the menstrual cycle has been studied in conjunction with test scores. When completing empathy exercises, women in the follicular stage of their menstrual cycle performed better than women in their midluteal phase. A significant correlation between progesterone levels and the ability to accurately recognize emotion was found. Performances on emotion recognition tasks were better when women had lower progesterone levels. Women in the follicular stage showed higher emotion recognition accuracy than their midluteal phase counterparts. Women were found to react more to negative stimuli when in midluteal stage over the women in the follicular stage, perhaps indicating more reactivity to social stress during that menstrual cycle phase. Overall, it has been found that women in the follicular phase demonstrated better performance in tasks that contain empathetic traits.
Fear response in women during two different points in the menstrual cycle has been examined. When estrogen is highest in the preovulatory stage, women are significantly better at identifying expressions of fear than women who were menstruating, which is when estrogen levels are lowest. The women were equally able to identify happy faces, demonstrating that the fear response was a more powerful response. To summarize, menstrual cycle phase and the estrogen levels correlates with womens fear processing.
However, the examination of daily moods in women with measuring ovarian hormones may indicate a less powerful connection. In comparison to levels of stress or physical health, the ovarian hormones had less of an impact on overall mood. This indicates that while changes of ovarian hormones may influence mood, on a day-to-day level it does not influence mood more than other stressors do.
Sexual feelings and behaviors change during the menstrual cycle. Before and during ovulation, high levels of estrogen and androgens result in women having an increased interest in sexual activity. Unlike other animal species, women show interest in sex across all days of the menstrual cycle, regardless of fertility.
Behavior towards potential mating partners changes during different phases of the menstrual cycle. Near ovulation, women may have increased physical attraction and interest in attending social gatherings with men. During the fertile phase of the cycle, women appear to prefer males who are more masculine. The intensity of mate guarding differs across the phases of the cycle, with increased mate guarding occurring when women are fertile.
During the fertile phase, many women experience more attraction, fantasies and sexual interest for extra pair men but not for the primary partner. They also engage in extra-pair flirtations and demonstrate a preference for extra pair copulation.
Preferences for voice pitch change across the cycle. When seeking a short term mating partner, women may prefer a male with a low voice pitch, particularly during the fertile phase. During the late follicular phase, it is common for women demonstrate a preference for mates with a masculine, deep voice. Research has also been conducted on the attractiveness of the female voice throughout the cycle. During their most fertile phase of the menstrual cycle, there is some evidence that female voices are rated as significantly more attractive. This effect is not found with women on the birth control pill.
Women's preference for male's body odor can change across the menstrual cycle. Males who score highly on dominance have been rated as sexier by females during the fertile phase of the menstrual cycle. Additionally, during their most fertile phase of the menstrual cycle, women may show preference for the odor of symmetrical men. This effect is not found for women on the birth control pill. Also, during the late follicular and ovulatory phases, women prefer the scent of masculine men. The scent of androsterone (responsible for testosterone levels) is highly preferred by women during the peak of their fertility in the menstrual cycle. Moreover, women may demonstrate preference for men with a scent that indicates developmental stability.
With regard to women's smell across the cycle, some evidence indicates that men use olfactory cues in order to know if a woman is ovulating. Using a rating of women's odors, women who are ovulating have been rated as more attractive by men. Men demonstrate preferences for the scent of fertile women.
Preferences for facial features in mates can also change across the cycle. There has been no difference found in preference for long-term mating partners during the menstrual cycle; however, those seeking a short-term relationship were more likely to choose a partner with more masculine features than usual. This was found to be the case especially during the woman's high conception risk stage and when salivary testosterone was high. However, when women are in the luteal (non-fertile) phase, they tend to prefer men (and females) with more feminine faces. A preference is also shown for self-resembling faces and apparent health in faces during the luteal phase of the cycle. Apparent health preferences were found to be strongest when progesterone levels were high. Additionally, during the fertile phase, many women show a preference for men with darker skin pigmentation. Research on facial symmetry is mixed.
Preferences for body features can change during the fertile phase of the cycle. Women seeking a short-term partner demonstrate a preference for taller and muscular males. Women also show preferences of males with masculine bodies at peak fertility. Mixed research has been found regarding body symmetry preferences throughout different phases of the cycle.
In short term mates, during the fertile phase, women may show more attraction to dominant men who display social presence. For long-term mates, shifts in desired trait preferences do not occur throughout the cycle.
Females have been found to experience different eating habits at different stages of their menstrual cycle, with food intake being higher during the luteal phase than the follicular phase. Food intake increases by approximately 10% during the luteal phase compared to the follicular phase.
Various studies have shown that during the luteal phase woman consume more carbohydrates, proteins and fats and that 24-hour energy expenditure shows increases between 2.5-11.5%. The increasing intake during the luteal phase may be related to higher preferences for sweet and fatty foods, which occurs naturally and is enhanced during the luteal phases of the menstrual cycle. This is due to the higher metabolic demand during this phase. In particular, women tend to show a cravings for chocolate, with higher cravings during the luteal phase.
Females with premenstrual syndrome (PMS) report changes in appetite across the menstrual cycle more than non-sufferers of PMS, possibly due to their oversensitivity to changes in hormone levels. In women with PMS, food intake is higher in the luteal phase than follicular. The remaining symptoms of PMS, including mood changes and physical symptoms, also occur during the luteal phase. No difference for preference of food types has been found between PMS sufferers and non-sufferers.
The different levels of ovarian hormones at different stages of the cycle have been used to explain eating behaviour changes. Progesterone has been shown to promote fat storage, causing a higher intake of fatty foods during the luteal phase when progesterone levels are higher. Additionally, with a high estrogen level dopamine is ineffective in converting to noradrenaline, a hormone which promotes eating, therefore decreasing appetite. In humans, the level of these ovarian hormones during the menstrual cycle have been found to influence binge eating.
It is theorized that the use of birth control pills should affect eating behaviour as they minimise or remove the fluctuations in hormone levels. The neurotransmitter serotonin is also thought to play a role in food intake. Serotonin is responsible for inhibiting eating and controlling meal size, among other things, and is modulated in part by ovarian hormones.
A number of factors affect whether dieting will affect these menstrual processes: age, weight loss and the diet itself. First, younger women are likely to experience menstrual irregularities due to their diet. Second, menstrual abnormalities are more likely with more weight loss. For example, anovulatory cycles can occur as a result of adopting a restricted diet, as well as engaging in a high amount of exercise. Finally, the cycle is affected more by a vegetarian diet compared to a non-vegetarian diet.
Studies investigating effects of the menstrual cycle on alcohol consumption have found mixed evidence. However, some evidence suggests that individuals consume more alcohol during the luteal stage, especially if these individuals are heavy drinkers or have a family history of alcohol abuse.
The level of substance abuse increases with PMS, mostly with addictive substances such as nicotine, tobacco and cocaine. One theory behind this suggests this higher level of substance abuse is due to decreased self-control as a result of the higher metabolic demands during the luteal phase.
Infrequent or irregular ovulation is called oligoovulation. The absence of ovulation is called anovulation. Normal menstrual flow can occur without ovulation preceding it: an anovulatory cycle. In some cycles, follicular development may start but not be completed; nevertheless, estrogens will be formed and stimulate the uterine lining. Anovulatory flow resulting from a very thick endometrium caused by prolonged, continued high estrogen levels is called estrogen breakthrough bleeding. Anovulatory bleeding triggered by a sudden drop in estrogen levels is called withdrawal bleeding. Anovulatory cycles commonly occur before menopause (perimenopause) and in women with polycystic ovary syndrome.
Very little flow (less than 10 ml) is called hypomenorrhea. Regular cycles with intervals of 21 days or fewer are polymenorrhea; frequent but irregular menstruation is known as metrorrhagia. Sudden heavy flows or amounts greater than 80 ml are termed menorrhagia. Heavy menstruation that occurs frequently and irregularly is menometrorrhagia. The term for cycles with intervals exceeding 35 days is oligomenorrhea.Amenorrhea refers to more than three to six months without menses (while not being pregnant) during a woman's reproductive years. The term for painful periods is Dysmenorrhea.
The menstrual cycle can be described by the ovarian or uterine cycle. The ovarian cycle describes changes that occur in the follicles of the ovary whereas the uterine cycle describes changes in the endometrial lining of the uterus. Both cycles can be divided into three phases. The ovarian cycle consists of the follicular phase, ovulation, and the luteal phase, whereas the uterine cycle consists of menstruation, proliferative phase, and secretory phase.
The follicular phase is the first part of the ovarian cycle. During this phase, the ovarian follicles mature and get ready to release an egg. The latter part of this phase overlaps with the proliferative phase of the uterine cycle.
Through the influence of a rise in follicle stimulating hormone (FSH) during the first days of the cycle, a few ovarian follicles are stimulated. These follicles, which were present at birth and have been developing for the better part of a year in a process known as folliculogenesis, compete with each other for dominance. Under the influence of several hormones, all but one of these follicles will stop growing, while one dominant follicle in the ovary will continue to maturity. The follicle that reaches maturity is called a tertiary or Graafian follicle, and it contains the ovum.
Ovulation is the second phase of the ovarian cycle in which a mature egg is released from the ovarian follicles into the oviduct. During the follicular phase, estradiol suppresses release of luteinizing hormone (LH) from the anterior pituitary gland. When the egg has nearly matured, levels of estradiol reach a threshold above which this effect is reversed and estrogen stimulates the production of a large amount of LH. This process, known as the LH surge, starts around day12 of the average cycle and may last 48 hours.
The exact mechanism of these opposite responses of LH levels to estradiol is not well understood. In animals, a gonadotropin-releasing hormone (GnRH) surge has been shown to precede the LH surge, suggesting that estrogen's main effect is on the hypothalamus, which controls GnRH secretion. This may be enabled by the presence of two different estrogen receptors in the hypothalamus: estrogen receptor alpha, which is responsible for the negative feedback estradiol-LH loop, and estrogen receptor beta, which is responsible for the positive estradiol-LH relationship. However, in humans it has been shown that high levels of estradiol can provoke 32 increases in LH, even when GnRH levels and pulse frequencies are held constant, suggesting that estrogen acts directly on the pituitary to provoke the LH surge.
The release of LH matures the egg and weakens the wall of the follicle in the ovary, causing the fully developed follicle to release its secondary oocyte. If it is fertilized by a sperm, the secondary oocyte promptly matures into an ootid and then becomes a mature ovum. If it is not fertilized by a sperm, the secondary oocyte will degenerate. The mature ovum has a diameter of about 0.2mm.
Which of the two ovariesleft or rightovulates appears essentially random; no known left and right co-ordination exists. Occasionally, both ovaries will release an egg; if both eggs are fertilized, the result is fraternal twins.
After being released from the ovary, the egg is swept into the fallopian tube by the fimbria, which is a fringe of tissue at the end of each fallopian tube. After about a day, an unfertilized egg will disintegrate or dissolve in the fallopian tube.
Fertilization by a spermatozoon, when it occurs, usually takes place in the ampulla, the widest section of the fallopian tubes. A fertilized egg immediately begins the process of embryogenesis, or development. The developing embryo takes about three days to reach the uterus and another three days to implant into the endometrium. It has usually reached the blastocyst stage at the time of implantation.
In some women, ovulation features a characteristic pain called mittelschmerz (German term meaning middle pain). The sudden change in hormones at the time of ovulation sometimes also causes light mid-cycle blood flow.
The luteal phase is the final phase of the ovarian cycle and it corresponds to the secretory phase of the uterine cycle. During the luteal phase, the pituitary hormones FSH and LH cause the remaining parts of the dominant follicle to transform into the corpus luteum, which produces progesterone. The increased progesterone in the adrenals starts to induce the production of estrogen. The hormones produced by the corpus luteum also suppress production of the FSH and LH that the corpus luteum needs to maintain itself. Consequently, the level of FSH and LH fall quickly over time, and the corpus luteum subsequently atrophies. Falling levels of progesterone trigger menstruation and the beginning of the next cycle. From the time of ovulation until progesterone withdrawal has caused menstruation to begin, the process typically takes about two weeks, with 14 days considered normal. For an individual woman, the follicular phase often varies in length from cycle to cycle; by contrast, the length of her luteal phase will be fairly consistent from cycle to cycle.
The loss of the corpus luteum is prevented by fertilization of the egg. The syncytiotrophoblast, which is the outer layer of the resulting embryo-containing structure (the blastocyst) and later also becomes the outer layer of the placenta, produces human chorionic gonadotropin (hCG), which is very similar to LH and which preserves the corpus luteum. The corpus luteum can then continue to secrete progesterone to maintain the new pregnancy. Most pregnancy tests look for the presence of hCG.
The uterine cycle has three phases: menses, proliferative, secretory.
Menstruation (also called menstrual bleeding, menses, catamenia or a period) is the first phase of the uterine cycle. The flow of menses normally serves as a sign that a woman has not become pregnant. (However, this cannot be taken as certainty, as a number of factors can cause bleeding during pregnancy; some factors are specific to early pregnancy, and some can cause heavy flow.)
Eumenorrhea denotes normal, regular menstruation that lasts for a few days (usually 3 to 5 days, but anywhere from 2 to 7 days is considered normal). The average blood loss during menstruation is 35 milliliters with 1080 ml considered normal. Women who experience Menorrhagia are more susceptible to iron deficiency than the average person. An enzyme called plasmin inhibits clotting in the menstrual fluid.
Painful cramping in the abdomen, back, or upper thighs is common during the first few days of menstruation. Severe uterine pain during menstruation is known as dysmenorrhea, and it is most common among adolescents and younger women (affecting about 67.2% of adolescent females). When menstruation begins, symptoms of premenstrual syndrome (PMS) such as breast tenderness and irritability generally decrease. Many sanitary products are marketed to women for use during their menstruation.
The proliferative phase is the second phase of the uterine cycle when estrogen causes the lining of the uterus to grow, or proliferate, during this time. As they mature, the ovarian follicles secrete increasing amounts of estradiol, and estrogen. The estrogens initiate the formation of a new layer of endometrium in the uterus, histologically identified as the proliferative endometrium. The estrogen also stimulates crypts in the cervix to produce fertile cervical mucus, which may be noticed by women practicing fertility awareness.
The secretory phase is the final phase of the uterine cycle and it corresponds to the luteal phase of the ovarian cycle. During the secretory phase, the corpus luteum produces progesterone, which plays a vital role in making the endometrium receptive to implantation of the blastocyst and supportive of the early pregnancy, by increasing blood flow and uterine secretions and reducing the contractility of the smooth muscle in the uterus; it also has the side effect of raising the woman's basal body temperature.
While some forms of birth control do not affect the menstrual cycle, hormonal contraceptives work by disrupting it. Progestogen negative feedback decreases the pulse frequency of gonadotropin-releasing hormone (GnRH) release by the hypothalamus, which decreases the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) by the anterior pituitary. Decreased levels of FSH inhibit follicular development, preventing an increase in estradiol levels. Progestogen negative feedback and the lack of estrogen positive feedback on LH release prevent a mid-cycle LH surge. Inhibition of follicular development and the absence of a LH surge prevent ovulation.
The degree of ovulation suppression in progestogen-only contraceptives depends on the progestogen activity and dose. Low dose progestogen-only contraceptivestraditional progestogen only pills, subdermal implants Norplant and Jadelle, and intrauterine system Mirenainhibit ovulation in about 50% of cycles and rely mainly on other effects, such as thickening of cervical mucus, for their contraceptive effectiveness. Intermediate dose progestogen-only contraceptivesthe progestogen-only pill Cerazette and the subdermal implant Nexplanonallow some follicular development but more consistently inhibit ovulation in 9799% of cycles. The same cervical mucus changes occur as with very low-dose progestogens. High-dose, progestogen-only contraceptivesthe injectables Depo-Provera and Noristeratcompletely inhibit follicular development and ovulation.
Combined hormonal contraceptives include both an estrogen and a progestogen. Estrogen negative feedback on the anterior pituitary greatly decreases the release of FSH, which makes combined hormonal contraceptives more effective at inhibiting follicular development and preventing ovulation. Estrogen also reduces the incidence of irregular breakthrough bleeding. Several combined hormonal contraceptivesthe pill, NuvaRing, and the contraceptive patchare usually used in a way that causes regular withdrawal bleeding. In a normal cycle, menstruation occurs when estrogen and progesterone levels drop rapidly. Temporarily discontinuing use of combined hormonal contraceptives (a placebo week, not using patch or ring for a week) has a similar effect of causing the uterine lining to shed. If withdrawal bleeding is not desired, combined hormonal contraceptives may be taken continuously, although this increases the risk of breakthrough bleeding.
Breastfeeding causes negative feedback to occur on pulse secretion of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH). Depending on the strength of the negative feedback, breastfeeding women may experience complete suppression of follicular development, but no ovulation, or normal menstrual cycle may resume. Suppression of ovulation is more likely when suckling occurs more frequently. The production of prolactin in response to suckling is important to maintaining lactational amenorrhea. On average, women who are fully breastfeeding whose infants suckle frequently experience a return of menstruation at fourteen and a half months postpartum. There is a wide range of response among individual breastfeeding women, however, with some experiencing return of menstruation at two months and others remaining amenorrheic for up to 42 months postpartum.
The word "menstruation" is etymologically related to "moon". The terms "menstruation" and "menses" are derived from the Latin mensis (month), which in turn relates to the Greek mene (moon) and to the roots of the English words month and moon.
Even though the average length of the human menstrual cycle is similar to that of the lunar cycle, in modern humans there is no relation between the two. The relationship is believed to be a coincidence. Light exposure does not appear to affect the menstrual cycle in humans. A meta-analysis of studies from 1996 showed no correlation between the human menstrual cycle and the lunar cycle, nor did data analysed by period-tracking app Clue, submitted by 1.5m women, of 7.5m menstrual cycles.
Dogon villagers did not have electric lighting and spent most nights outdoors, talking and sleeping, so they were apparently an ideal population for detecting a lunar influence; none was found.
In a number of countries, mainly in Asia, legislation or corporate practice has introduced formal menstrual leave to provide women with either paid or unpaid leave of absence from their employment while they are menstruating. Countries with policies include Japan, Taiwan, Indonesia, and South Korea. The practice is controversial due to concerns that it bolsters the perception of women as weak, inefficient workers, as well as concerns that it is unfair to men.
Media related to Menstrual cycle at Wikimedia Commons
Read this article:
Menstrual cycle - Wikipedia
- Analysis Determines Cost Effectiveness of Various Treatment Strategies for Multiple Myeloma - Cancer Therapy Advisor - October 11th, 2019
- Stem cell therapy helped Owen Franks but there's still plenty to prove - Stuff.co.nz - October 11th, 2019
- AgeX Therapeutics to Present at Metabesity 2019 - Business Wire - October 11th, 2019
- Stem Cell Characterization Kits Market 08-Year Market Forecast and Trends Analysis Research Report - The Tribune City - October 10th, 2019
- New Cambridge research could lead to novel cancer therapies - Business Weekly - October 10th, 2019
- Global 3D Bioprinting Market Outlook, 2019-2024 - Market Anticipated to Reach $1.64 Billion by 2024 - ResearchAndMarkets.com - Business Wire - October 10th, 2019
- Stem Cell Cartilage Regeneration Market 2019: Prosperous Growth, Recent Trends and Demand by Top Key Vendors like Anika Therapeutics, Biomet,... - October 10th, 2019
- Industry Champion Jim Greenwood to Retire Following 2020 Elections - BioSpace - October 10th, 2019
- Cell Culture Protein Surface Coatings Market will Going to be Worth US$ 623.4 Mn by 2020 - Online News Guru - October 10th, 2019
- NIH funding bolsters rare diseases research collaborations | National Institutes of Health - National Institutes of Health - October 4th, 2019
- Stem Cell Therapy Market worth USD 4759.27 Million By 2024 - Global Market News 24 - October 4th, 2019
- Genome editing to be tested in kidney organoids - UW Medicine Newsroom - October 2nd, 2019
- First Patient Enrolled in Novel Stem Cell Trial for Heart Failure Treatment - Newswise - October 2nd, 2019
- Vor Biopharma Hires Senior Cell and Gene Therapy Leaders as Chief Technology Officer and Vice President of Research - Business Wire - October 2nd, 2019
- Now in development: off-the-shelf stem cells - Knowable Magazine - September 28th, 2019
- Immunity Against Cancer? Engineered Killer T Cells May Be the Key. - SciTechDaily - September 28th, 2019
- 'Provocative' Results With Stem Cells in Progressive MS - Medscape - September 27th, 2019
- 'I've Been Duped': Disabled Veteran Says He Spent Thousands at Health Center With No Improvement - NBC Bay Area - September 27th, 2019
- Finding alternatives to animal testing - University of California - September 27th, 2019
- Gene therapy shows promise repairing brain tissue damaged by stroke - National Institute on Aging - September 27th, 2019
- Vitro Biopharma 3rd Quarter ended July 31st 2019 Financial Results of Operations - Yahoo Finance - September 27th, 2019
- Science Talk - Celebrating Professor Sir Mel Greaves and his legacy in leukaemia research - The Institute of Cancer Research - September 27th, 2019
- New restrictions put fetal tissue research in the balance - AAMCNews - September 25th, 2019
- 'I've Been Duped': Disabled Veteran Says He Spent Thousands at Health Center With No Improvement - NBC Southern California - September 25th, 2019
- New Research Suggests a Cure for HIV Could be on the Horizon - BioSpace - September 25th, 2019
- iSpecimen Increases Global Access to Hematopoietic Stem and Immune Cells - Business Wire - September 25th, 2019
- Alternative medical treatments and compassionate use - Lexology - September 25th, 2019
- Stem Cell Market to witness huge Growth during the forecast period 2019-2025: Advanced Cell Technology Inc, Cellartis AB, STEMCELL Technologies Inc ... - September 25th, 2019
- It's not 'sorry' but 'thank you' that seems to be the hardest word - Charity Today News - September 25th, 2019
- New Insight as to How Cells Maintain Their Identity - Nature World News - September 22nd, 2019
- Abortion opponents hold memorials at fetal burial sites amid battle over how these remains should be treated - Walla Walla Union-Bulletin - September 22nd, 2019
- Global Cell Isolation/Cell Separation Market Industry Analysis and Forecast (2019-2026) - ScoopJunction - September 22nd, 2019
- Can old drugs put a leash on wandering cancer cells? - Newsroom - September 22nd, 2019
- Circulating Tumor Cells and Cancer Stem Cells Market Estimated to Expand at a Robust CAGR over 2025 - Commerce Gazette - September 22nd, 2019
- Sask. woman reflects on cancer journey before leading inaugural Multiple Myeloma March - News Talk 980 CJME - September 22nd, 2019
- Global Induced Pluripotent Stem Cells (iPSCs) Market Size, Status and Forecast 2019-2025 - Rapid News Network - September 22nd, 2019
- Global Stem Cell Therapy Market Analysis and Forecast, 2019-2029: Focus on Treatment Type, Cell Source, Indication,11 Countries' Data, and Competitive... - September 21st, 2019
- 4 Stocks to Focus on Global Biotechnology Reagents Market - Yahoo Finance - September 21st, 2019
- Editing Muscle Stem Cells with CRISPR Treats Mouse Model of Muscular Dystrophy - DocWire News - September 21st, 2019
- Mutant Tau Stiffens Axon Cytoskeleton Near Soma - Alzforum - September 21st, 2019
- Testing chemicals for birth defects using stem cells, not mice - UC Riverside - September 21st, 2019
- Global Cell Harvesting Market is Booming Market to Rapidly Growing $ 387.9 Million by 2026 with Top Key Players PerkinElmer Inc, Bertin, Tomtec,... - September 21st, 2019
- Stem Cells May Be Able To Repair The Brain - Anti Aging News - September 20th, 2019
- MS News that Caught My Eye: Stem Cell Transplants, Remyelination Agent, Tecfidera Study, Plasma Exchange and Tysabri-linked PML - Multiple Sclerosis... - September 20th, 2019
- Tiny 'envelopes' show promise for sun-damaged skin repair - Futurity: Research News - September 20th, 2019
- Hope for Sickle Cell Warriors: A Cure Exists and Support from the Black Community Could Help Save More Lives - EBONY - September 20th, 2019
- Latest Report on Stem Cell Therapy Market To Flourish And Reach USD 4759.27 Million By 2024 - News Hours Today - September 20th, 2019
- Ruth Lehmann elected as director of Whitehead Institute - MIT News - September 20th, 2019
- Regulatory heft needed to curb false promises on stem cells, says health law expert - Folio - University of Alberta - September 20th, 2019
- Releases New Report on the Stem Cell Banking Market 2017-2025 - Rapid News Network - September 20th, 2019
- In Mice and Men, Prostate Drug Reportedly Treats Parkinson's Disease? - Alzforum - September 20th, 2019
- Stem Cell-Derived Cells Market to Record an Exponential CAGR by 2025 - Commerce Gazette - September 20th, 2019
- Global & US Gene Therapy Market 2019-2020: Immunodeficiency Syndromes - The Focus of Gene Therapy - PRNewswire - September 20th, 2019
- Ten-Year Bone Cancer Survivor Rides 'Coast 2 Coast' - Curetoday.com - September 20th, 2019
- Cancer Stem Cell Market Size Research Study including Growth Factors, Types and Application to 2025 - Daily News Collectors - September 20th, 2019
- Current State Of Longevity Clinical Trials - Anti Aging News - September 20th, 2019
- Crigler-Najjar Syndrome Market Insights 2019-2026: Audentes Therapeutics Inc, Genethon SA, International Stem Cell Corp - US Trade Media - September 20th, 2019
- Global Stem Cell Antibody Market Analysis, Growth, Size, Share, Demand & Forecast 2019-2026: Thermo Fisher Scientific, Inc., Merck Group, Abcam... - September 20th, 2019
- Reported stem cell treatment could give hope to Michael Schumacher - Stuff.co.nz - September 18th, 2019
- USC researchers untangle cellular reprogramming to help treat diseases - USC News - September 18th, 2019
- India- Cell Counting Market Size is Estimated to Value $10679.7 Million By 2025: Grand View Research, Inc - MENAFN.COM - September 18th, 2019
- CyTOF Inventors Receive Prestigious Science and Technology Award from the Human Proteome Organization (HUPO) - Yahoo Finance - September 18th, 2019
- Genome-editing shows potential for treating HIV in patient - BioNews - September 18th, 2019
- New technology developed to screen for Huntington's treatments - Drug Target Review - September 18th, 2019
- Device can produce synthetic human embryo-like parts - Washington Times - September 18th, 2019
- Global Advanced Wound Care Markets to 2024: Emerging Technologies such as Crab Shell Bandages, Bacteriophages, Platelets, and Stem Cell Therapies are... - September 18th, 2019
- Growth of the Global Cord Blood Stem Cell Market Driven by Improvements in Product Design - Business Broker - September 18th, 2019
- Couple give embryos, 'hope' to UM in fight against rare disease - The Detroit News - September 18th, 2019
- Induced Pluripotent Stem Cell Market Estimated to be Driven by Innovation and Industrialization - Wolf Mirror - September 18th, 2019
- Research: By exploiting a feature of the immune system, researchers open the door for stem cell transplants to repair the brain - Tdnews - September 18th, 2019
- Study Of Stem Cell Cartilage Regeneration Market And Also Elements For Its Future Growth 2026 - Coherent Magazine - September 18th, 2019
- Attorney General trying to intimidate witness testifying about live fetal hearts: lawyers - Lifesite - September 18th, 2019
- Global Stem Cell Therapy Market Expects an Extensive Growth in ROI of USD 4759.27 Million By 2024 - News Hours Today - September 18th, 2019
- Demand for Stem Cell-Derived Cells Market Driven by Shifting Consumer Perceptions and Growing Awareness - My Health Reporter - September 18th, 2019
- Major Players of Serum-Free Media Market By Type: protein expression media, stem cell media, hybridoma media, primary cell media, insect cell media -... - September 18th, 2019
- Cancer Stem Cell Market Insights on Upcoming Trends 2025 - Spaceflight News - September 18th, 2019
- X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development - Business Wire - September 18th, 2019
- Pathogenic Escherichia coli | Nature Reviews Microbiology - May 27th, 2019
- Pathways to Stem Cell Science | Pluripotent Stem Cell ... - May 14th, 2019
- What are the unique properties of stem cells - answers.com - May 2nd, 2019